Effects of Left Atrial Appendage Occlusion

Withdrawn before enrolling

Conditions studied: Atrial Fibrillation

In brief

The proposed work seeks to further understand the effects of LAA occlusion on cardiac structure and function, and in homeostasis. Numerous studies have implicated the left atrial appendage (LAA) as the source of the vast majority of left atrial thrombi in the setting of AF3. The University of Pittsburgh Medical Center will be implanting a Left Atrial Appendage filter system (the WATCHMAN® Left Atrial Appendage Filter System, manufactured by Atritech, Inc.). We aim to follow these patients for six months post implant in order to assess their heart rhythm, function, and to do blood tests to evaluate for neurohormonal changes.

Key facts

Study ID

NCT00510900

Run by

University of Pittsburgh

People needed

0

Starts

2005-08-01

Expected to finish

2008-05-01

Last updated by the study team

2016-01-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years of age or older
• Ability to give informed consent.
• Patient will be enrolled in the WATCHMAN device trial at UPMC. 4 -Documented history of atrial fibrillation.

You may not qualify if…

• Inability to give informed consent

Where it is running

• University of Pittsburgh Medical Center/Comprehensive Heart Ctr. — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.